Serpentine supravenous hyperpigmentation (SSH) in nasopharyngeal carcinoma patient on docetaxel and carboplatin chemotherapy: a case report

  • Indry Salonika Sutiawan Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana/Sanglah General Hospital, Denpasar, Bali, Indonesia
  • Ni Made Dwi Puspawati Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana/Sanglah General Hospital, Denpasar, Bali, Indonesia
  • Adelia Martalova AJ Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana/Sanglah General Hospital, Denpasar, Bali, Indonesia
  • Alfred Setyono Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana/Sanglah General Hospital, Denpasar, Bali, Indonesia
  • Putu Akopita Devi Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana/Sanglah General Hospital, Denpasar, Bali, Indonesia
  • Ni Kadek Setyawati Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana/Sanglah General Hospital, Denpasar, Bali, Indonesia
Keywords: docetaxel;, carboplatin;, nasopharyngeal carcinoma;, serpentine supravenous hyperpigmentation;, side effects

Abstract

Serpentine supravenous hyperpigmentation (SSH) is a rare but unique side effect of intravenous anticancer. It manifests as linear hyperpigmentation eruption on the skin that radiates along the superficial vein accompanied by mild pain and/or itch. This SSH does not cause systemic alterations, however, most patients complained about its cosmetic effects. The diagnosis of SSH can be made clinically, although histopathological examinations can aid in excluding differential diagnoses. We reported a case of SSH found in a nasopharyngeal cancer patient during docetaxel and carboplatin chemotherapy. It is a potentially alarming interface dermatitis that is not lot reported in the literature. It was reported, the patient tolerated the second and third cycles well with less severe side effects when premedicated with 250 mL NaCl 0.9% bolus intravenously before and after chemotherapy sessions, 10 mg cetirizine every 24 hr orally, and desoximetasone cream 0.25% every 12 hr topically added.

Author Biography

Ni Kadek Setyawati, Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana/Sanglah General Hospital, Denpasar, Bali, Indonesia

 

 

Published
2024-05-02
Section
Articles